MEDVi's QUAD formula approaches erectile dysfunction from four simultaneous directions — Vardenafil, Sildenafil, Tadalafil, and Apomorphine — delivered in a sublingual tablet that dissolves under the tongue for faster absorption than standard oral ED pills. If you have tried standard sildenafil or tadalafil and found the results underwhelming or inconsistent, a multi-action sublingual format like MEDVi QUAD represents a meaningfully different therapeutic approach.
Comparing ed care providers? Check out our comprehensive Best ED Care Providers comparison to see how MEDVi ranks alongside other top options.
Quick-Look Summary
| Provider Name | MEDVi |
|---|---|
| Rating | 4.9 / 5.0 |
| Price Range | 4-in-1 Fast-acting ED treatment from $119/mo |
| Best For | Men looking for fast-acting, multi-ingredient ED support |
| Highlights | Top Rated |
What Is MEDVi?
MEDVi is a telehealth platform offering compounded erectile dysfunction medications. Their QUAD formula is their flagship ED product — a sublingual tablet combining three PDE5 inhibitors (Vardenafil, Sildenafil, Tadalafil) with Apomorphine, a dopamine agonist that supports neurological arousal and desire. Sublingual delivery allows the active ingredients to enter the bloodstream through the mucosal tissue under the tongue, bypassing first-pass liver metabolism and accelerating onset compared to tablets swallowed whole.
How It Works
The MEDVi process begins with a short online intake covering your health history, current medications, and ED symptoms. A licensed clinician reviews your case and, if eligible, prescribes the QUAD formula. Your medication is dispensed from a licensed compounding pharmacy and shipped discreetly. Onset is reported at 10–15 minutes, with coverage lasting up to 36 hours from a single dose — giving you a full day and a half of spontaneity without re-dosing.
Who Is MEDVi For?
MEDVi QUAD is best for men who want the broadest possible multi-pathway ED coverage in a single dose. It is particularly well-suited for men whose ED involves both vascular and psychological/arousal components, since the Apomorphine component targets the central nervous system in addition to the vascular mechanisms addressed by the three PDE5 inhibitors. Men who have found single-ingredient ED medications to produce unpredictable results may benefit most from the multi-drug approach.
Key Features
- 4-in-1 Formula: Vardenafil + Sildenafil + Tadalafil + Apomorphine
- Fast-acting sublingual - works in 10-15 minutes
- 36-hour coverage from single dose
- Boosts desire & performance
Pros & Cons
✔ Pros
- Multi-ingredient 4-in-1 blend
- Sublingual format designed for fast onset
- Extended coverage from a single dose
✗ Cons
- Not ideal for patients who prefer single-ingredient protocols
- Monthly pricing can vary by selected plan
Pricing
MEDVi's QUAD formula starts at $119/month, making it one of the more accessible multi-ingredient ED programs among telehealth providers. The sublingual format and the inclusion of all four active compounds justifies a premium over generic sildenafil or tadalafil alone. Exact pricing depends on the plan selected and clinician-assessed dosing. The consultation is included in the process, and there are no hidden fees before you receive your prescription.
Final Verdict
MEDVi QUAD stands out in a crowded ED market by combining three PDE5 inhibitors with Apomorphine in a sublingual format — producing faster onset and broader coverage than any single-ingredient option. For men who are beyond the stage of experimenting with basic generics and want clinically engineered multi-pathway support, MEDVi QUAD is a strong, well-priced option from a credible telehealth provider.
Want to compare more options? Check out our comprehensive ED Care providers comparison.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting or changing any medical treatment. Individual results may vary.
Disclosure: ExploreTreatments.com may earn a commission if you begin treatment through links on this page, at no additional cost to you. This does not influence our editorial assessment.